An Open-label Study Evaluating the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Tanruprubart Single Dose in Participants From North America and Europe With Guillain-Barr&#233; Syndrome

tanruprubart (ANX005) - Annexon Biosci

Shafeeq Ladha1; Rafid Mustafa2; Kavita Grover3; Glenn Morrison4; Ping Lin4; Henk-André Kroon4; Jeffrey Allen5

Mar 6, 2026